ArticleScience translational medicine2019
Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 89 citations in OpenAlex.
- Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia.Blood advances · 2020Trial
- Neoantigen Targeting as a Novel Approach for Therapy-Resistant Tumors.Molecular diagnosis & therapy · 2026Review
- The GF-NEO discovery platform unveils a [KQE][DG] sequence motif within fusion neoantigens in pediatric cancer.iScience · 2026Article
- Endogenous T cell responses to fusion-derived neoantigens in pediatric acute leukemias.Leukemia · 2025Article
- Somatic Mutations in DNA Mismatch Repair Genes, Mutation Rate and Neoantigen Load in Acute Lymphoblastic Leukemia.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Circulating tumor-associated and neoantigen-specific endogenous T cells in children treated for B-acute lymphoblastic leukemia.HemaSphere · 2025Article
- Memory-like Natural Killer Cell and CD19 Antibody-Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia.Cancer immunology research · 2025Article
- Adoptively transferred tumor-specific IL-9-producing cytotoxic CD8Nature cancer · 2025Article
- T cell exhaustion in pediatric B-ALL: current knowledge and future perspectives.Frontiers in immunology · 2025Review
- Review
- [Research progress of tumor-infiltrating lymphocytes in malignant hematological diseases].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Review
- Article
- DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma.Cell reports. Medicine · 2024Article
- Ontogeny shapes the ability of ETV6::RUNX1 to enhance hematopoietic stem cell self-renewal and disrupt early lymphopoiesis.Leukemia · 2024Article
- [Application and clinical significance of intercellular proximity labeling technique in chronic myelogenous leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Article
- Antigen-specific and cross-reactive T cells in protection and disease.Immunological reviews · 2023Review
- Identification and Targeting of Mutant Neoantigens in Multiple Myeloma Treatment.Current oncology (Toronto, Ont.) · 2023Review
- Computational prediction of MHC anchor locations guides neoantigen identification and prioritization.Science immunology · 2023Article
- Review
- Contribution of the TIME in BCP-ALL: the basis for novel approaches therapeutics.Frontiers in immunology · 2023Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
20 authors at 1 institution in 1 country.
Anthony E ZamoraDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.ORCID 0000-0001-5712-5339
Jeremy Chase CrawfordDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.ORCID 0000-0003-4096-6048
E Kaitlynn AllenDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.ORCID 0000-0002-3067-751X
Xi-Zhi J GuoDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.ORCID 0000-0002-5564-3287
Jesse BakkeDepartment of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.ORCID 0000-0003-0305-5165
Robert A CarterDepartment of Computational Biology and Bioinformatics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Hossam A AbdelsamedDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Ardiana MoustakiDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Yongjin LiDepartment of Computational Biology and Bioinformatics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Ti-Cheng ChangDepartment of Computational Biology and Bioinformatics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.ORCID 0000-0001-5302-9147
Walid AwadDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Mari H DallasDepartment of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.ORCID 0000-0001-6521-7065
Charles G MullighanDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.ORCID 0000-0002-1871-1850
James R DowningDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Terrence L GeigerDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.ORCID 0000-0001-8290-5732
Taosheng ChenDepartment of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Douglas R GreenDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Benjamin A YoungbloodDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Jinghui ZhangDepartment of Computational Biology and Bioinformatics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.ORCID 0000-0003-3350-9682
Paul G ThomasDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. paul.thomas@stjude.org.ORCID 0000-0001-7955-0256
St. Jude Children's Research Hospital · US
Funding
The DNA Damage Response and Tumorigenesis in the BrainP01CA096832 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI BAKER, SUZANNE J. · 2003 to 2025
$38.0MCPML - Project 3: Genome-wide Studies of Adverse EffectsP50GM115279 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI LOH, MIGNON LEE-CHEUN, RELLING, MARY V · 2015 to 2019
$15.1MTranslating genomic discoveries to improved outcomes for high risk acute leukemiaR35CA197695 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Charles G Mullighan · 2017 to 2026
$11.4MDECODING THE INTERACTIONS BETWEEN T CELL RECEPTORS AND PEPTIDE-MHCR01AI136514 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Paul G. Thomas · 2018 to 2026
$6.9MRegulation of xenobiotic receptors PXR and CAR: implications in drug dispositionR35GM118041 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Taosheng Chen · 2016 to 2026
$4.3MMechanisms to diversify repertoire and modify T cell activity after infectionR01AI107625 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI THOMAS, PAUL G. · 2013 to 2017
$2.3MEstablishment, maintenance, and consequences of asymmetric cell division in T cellsR01AI123322 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI GREEN, DOUGLAS R. · 2017 to 2021
$2.2MEpigenetic Regulation of T-cell Exhaustion During Treated Chronic HIV InfectionR01AI114442 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI YOUNGBLOOD, BENJAMIN ALAN · 2015 to 2019
$2.1MNCI NIH HHS P01 CA096832NCI NIH HHS R35 CA197695NIAID NIH HHS R01 AI107625NIAID NIH HHS R01 AI114442NIAID NIH HHS R01 AI123322NIAID NIH HHS R01 AI136514NIGMS NIH HHS P50 GM115279NIGMS NIH HHS R35 GM118041
Abstract
Cancer arises from the accumulation of genetic alterations, which can lead to the production of mutant proteins not expressed by normal cells. These mutant proteins can be processed and presented on the cell surface by major histocompatibility complex molecules as neoepitopes, allowing CD8
Indexed as
Antigen PresentationAntigens, NeoplasmCD8-Positive T-LymphocytesChildGenetic HeterogeneityHumansImmunodominant EpitopesPrecursor Cell Lymphoblastic Leukemia-LymphomaReproducibility of ResultsTranscription, GeneticAntigens, NeoplasmImmunodominant Epitopes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.